Merck and Eisai said on Friday a combination of their cancer therapies failed to extend the lives of patients with a type of ...
The phase III ESCORT-NEO trial evaluated camrelizumab in combination with chemotherapy versus chemotherapy alone in the ...
1don MSN
Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis, and understanding the ...
Our study used a methodically rigorous process to identify biomarkers, and we believe this represents the first study to ...
Two U.S. companies teamed up to treat cancer patients using an unproven blood filter in Antigua, out of reach of American ...
Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.
(HealthDay News) — For patients with resectable esophageal adenocarcinoma, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) leads to improved survival ...
CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.
Baseline characteristics were generally well balanced between the arms. In the perioperative chemotherapy arm, patients received fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT). In the ...
For patients with resectable esophageal adenocarcinoma, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) leads to improved survival compared with ...
Researchers sought to determine postoperative outcomes of robot-assisted minimally invasive esophagectomy, LMIE, hybrid, and open surgical procedures for esophageal cancer.
Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback